Inspire Investing
PCRX icon

Inspire Investing’s Pacira BioSciences PCRX Stock Holding History

Inspire Investing’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$632K Sell
25,226
-1,619
-6% -$41K 0.03% 806
2026
Q2 		$681K Buy
26,845
+4,271
+19% +$101K 0.03% 672
2026
Q1 		$510K Buy
22,574
+4,616
+26% +$103K 0.03% 806
2025
Q4 		$465K Buy
17,958
+556
+3% +$13.2K 0.04% 699
2025
Q3 		$448K Buy
17,402
+846
+5% +$20.8K 0.04% 729
2025
Q2 		$396K Buy
16,556
+2,868
+21% +$72.3K 0.04% 358
2025
Q1 		$340K Sell
13,688
-7,347
-35% -$176K 0.04% 700
2024
Q4 		$396K Sell
21,035
-6,439
-23% -$113K 0.04% 737
2024
Q3 		$413K Buy
27,474
+15,138
+123% +$259K 0.04% 475
2024
Q2 		$353K Buy
12,336
+205
+2% +$5.84K 0.04% 494
2024
Q1 		$354K Buy
12,131
+675
+6% +$20.7K 0.04% 768
2023
Q4 		$387K Buy
11,456
+1,526
+15% +$44.6K 0.04% 445
2023
Q3 		$305K Buy
9,930
+2,083
+27% +$75.1K 0.04% 760
2023
Q2 		$314K Buy
7,847
+1,173
+18% +$48.5K 0.04% 542
2023
Q1 		$272K Buy
6,674
+595
+10% +$23.7K 0.03% 669
2022
Q4 		$235K Buy
6,079
+2,214
+57% +$108K 0.03% 680
2022
Q3 		$206K Buy
3,865
+188
+5% +$10.5K 0.03% 649
2022
Q2 		$214K Buy
3,677
+574
+18% +$37.6K 0.03% 379
2022
Q1 		$237K Sell
3,103
-1,015
-25% -$67.7K 0.03% 433
2021
Q4 		$248K Buy
4,118
+91
+2% +$5.02K 0.03% 592
2021
Q3 		$226K Buy
4,027
+67
+2% +$3.86K 0.03% 684
2021
Q2 		$240K Buy
3,960
+120
+3% +$7.6K 0.03% 568
2021
Q1 		$269K Sell
3,840
-4
-0.1% -$286 0.04% 551
2020
Q4 		$230K Buy
+3,844
New +$225K 0.05% 566
2020
Q3 		– Sell
-4,154
Closed -$218K – 537
2020
Q2 		$218K Sell
4,154
-1,439
-26% -$60.1K 0.08% 398
2020
Q1 		$188K Buy
+5,593
New +$232K 0.08% 473
2018
Q1 		– Sell
-1,298
Closed -$59K – 553
2017
Q4 		$59K Buy
+1,298
New +$51.4K 0.05% 358

Other funds holding PCRX

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Ellsworth Advisors
Ellsworth Advisors Hudson, Ohio $620M AUM 38.17% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Louisiana State Employees Retirement System
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Inspire Investing's PCRX Position: Q3 2026 in Review

Inspire Investing reduced its Pacira BioSciences (PCRX) stake by 6% in Q3 2026, selling an estimated $41K and leaving 25,226 shares worth $632K. The position accounts for 0.03% of the portfolio, ranked #806.

Inspire Investing first reported a position in PCRX in Q4 2017 and has held it in 27 quarters since. The position peaked at $681K in Q2 2026. 37 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Inspire Investing held 25,226 shares of Pacira BioSciences worth $632K as of Q3 2026.
  • Inspire Investing sold 1,619 Pacira BioSciences shares in Q3 2026, an estimated $41K.
  • Pacira BioSciences made up 0.03% of Inspire Investing's portfolio in Q3 2026, its #806 holding.
  • Inspire Investing first reported a position in Pacira BioSciences in Q4 2017 and has held it in 27 quarters since.
  • Inspire Investing's Pacira BioSciences position peaked at $681K in Q2 2026.
  • 37 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Inspire Investing's 13F filing for Q3 2026, filed 22 Oct 2026.